NDAORALTABLET
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ACCURETIC (hydrochlorothiazide; quinapril hydrochloride) by R-Pharm US is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 1999.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACCURETIC is a fixed-dose combination of quinapril hydrochloride (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) administered orally as a tablet for the treatment of hypertension. It works by inhibiting angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, while the diuretic component increases sodium and water excretion. The combination provides complementary mechanisms to achieve superior blood pressure control compared to monotherapy.
LOE Approaching
ACCURETIC is approaching loss of exclusivity, signaling potential team consolidation and transition toward managed care/generic defense initiatives.
Mechanism of Action
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Indications (1)
Worked on ACCURETIC at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.